Aims: The aim of the study was to evaluate the social impact of the COVID-19 pandemic on youth with diabetes in Northeast Ohio from March 2020 through October 2022, and assess for disparate impact on minority and socially disadvantaged groups.

Methods: An email survey was distributed to 609 families of children with diabetes who met the inclusion criteria: age 7-20 years, followed by our clinic, and T1DM (duration 2+ years) or T2DM (duration 1+ years) prior to the pandemic. The survey asked several questions in 5 categories (housing, guardian's job loss, medical care disruption, schooling disruption and death of household member from COVID-19). Responding yes to any question in a category constituted an adverse social event (ASE). COVID-19 infection, hospitalization and vaccination status were collected. Between group differences were examined with a Fisher's Exact Test.

Results: Sixty two parents (10%) answered the survey, of whom 33 (53%) reported no ASE, 22 (35%)reported one ASE, and 7 (11%) reported 2 or more ASEs. Six respondents were Black and five were Hispanic. Among Black participants 1 (17%) had 1 ASE and 1 (17%) had 2 or more ASE, which was not statistically different than White participants. Among Hispanic participants 2 (40%) had one ASE and2 (40%) had 2 or more ASEs, which was numerically higher than the rates seen in non-Hispanic participants and approached statistical significance, p=0.068. Rates of ASE did not differ by insurance type or income level. Rates of COVID-19 infection and hospitalization did not differ between racial and ethnic groups. COVID 19 vaccination occurred at similar rates for Black and White participants; however, only 20% of Hispanic children received a COVID-19 vaccination, compared to 70% of non-Hispanic participants, p=0.04.

Conclusion: Forty six percent of children with diabetes experienced one or more ASE during theCOVID-19 pandemic. Our survey suggests that rates of ASE may have been higher in Hispanicchildren, who were also less likely to receive a COVID-19 vaccine.

Disclosure

R.Abdul wahed: None. S.Ronis: None. S.A.Macleish: Speaker's Bureau; Insulet Corporation. J.R.Wood: Research Support; Insulet Corporation, Boehringer-Ingelheim, MannKind Corporation. S.Malay: None. K.A.Kutney: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.